Rilvegostomig (Anti-PD-1 & TIGIT)

Rilvegostomig is a bispecific humanized IgG1 antibody that targets the immunoregulatory receptor programmed cell death protein 1 (PD-1) and the co-inhibitory immune checkpoint molecule T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT) . It enhances T-cell activation and promotes a robust anti-tumor immune response, particularly in cancers like non-small cell lung cancer (NSCLC) . MW: 146.06.